Review

Molecular Immunology & Vaccine Research Lab, Pasteur Institute of Iran, Tehran, 13164, Iran

* Author for correspondence

Molecular Immunology & Vaccine Research Lab, Pasteur Institute of Iran, Tehran, 13164, Iran.

Email the corresponding author at s_rafati@yahoo.com

Published Online:4 Sep 2012https://doi.org/10.2217/imt.12.72

Abstract

A major role of chemokines is to mediate leukocyte migration through interaction with G-protein-coupled receptors. Various delivery systems have been developed to utilize the chemokine properties for combating disease. Viral and mutant viral vectors expressing chemokines, genetically modified dendritic cells with chemokine or chemokine receptors, engineered chemokine-expressing tumor cells and pDNA encoding chemokines are among these methods. Another approach for inducing a targeted immune response is fusion of a targeting antibody or antibody fragment to a chemokine. In addition, chemokines induce more effective antitumor immunity when used as adjuvants. In this regard, chemokines are codelivered along with antigens or fused as a targeting unit with antigenic moieties. In this review, several chemokines with their role in inducing immune response against different diseases are discussed, with a major emphasis on cancer.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell. Mol. Immunol.1(2),95–104 (2004).
Medline CASGoogle Scholar
2 Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv. Drug. Deliv. Rev.58(8),962–974 (2006).
Medline CASGoogle Scholar
3 Flanagan K, Kaufman HL. Chemokines in tumor immunotherapy. Front. Biosci.11,1024–1030 (2006).
Medline CASGoogle Scholar
4 Schaerli P, Moser B. Chemokines: control of primary and memory T-cell traffic. Immunol. Res.31(1),57–74 (2005).
Medline CASGoogle Scholar
5 Laing KJ, Secombes CJ. Chemokines. Dev. Comp. Immunol.28(5),443–460 (2004).
Medline CASGoogle Scholar
6 Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy1(1),109–127 (2009).
CASGoogle Scholar
7 Lillard JW Jr, Boyaka PN, Taub DD, McGhee JR. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol.166(1),162–169 (2001).
Medline CASGoogle Scholar
8 Lillard JW Jr, Boyaka PN, Hedrick JA, Zlotnik A, McGhee JR. Lymphotactin acts as an innate mucosal adjuvant. J. Immunol.162(4),1959–1965 (1999).
Medline CASGoogle Scholar
9 Dell’Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev. Vaccines6(2),267–283 (2007).
MedlineGoogle Scholar
10 Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol.72(1),9–18 (2002).
Medline CASGoogle Scholar
11 Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur. J. Cancer42(6),760–767 (2006).
Medline CASGoogle Scholar
12 Darash-Yahana M, Gillespie JW, Hewitt SM et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PloS ONE4(8),e6695 (2009).
MedlineGoogle Scholar
13 Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med.16(3),133–144 (2010).
Medline CASGoogle Scholar
14 Strieter RM, Polverini PJ, Kunkel SL et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem.270(45),27348–27357 (1995).
Medline CASGoogle Scholar
15 Addison CL, Daniel TO, Burdick MD et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR⁺ CXC chemokine-induced angiogenic activity. J. Immunol.165(9),5269–5277 (2000).
Medline CASGoogle Scholar
16 Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr. Opin Immunol.12(5),571–575 (2000).
Medline CASGoogle Scholar
17 De Gruijl TD, Van Den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol. Immunother.57(10),1569–1577 (2008).
MedlineGoogle Scholar
18 Moret-Tatay I, Diaz J, Marco FM, Crespo A, Alino SF. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther.10(12),887–897 (2003).
Medline CASGoogle Scholar
19 Schadendorf D, Paschen A, Sun Y. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol. Lett.74(1),67–74 (2000).
Medline CASGoogle Scholar
20 Gao JQ, Sugita T, Kanagawa N et al. Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. Biol. Pharm. Bull.28(6),1066–1070 (2005).
Medline CASGoogle Scholar
21 Gao JQ, Alexandre LS, Tsuda Y et al. Tumor-suppressive activities by chemokines introduced into OV-HM cells using fiber-mutant adenovirus vectors. Pharmazie59(3),238–239 (2004).
Medline CASGoogle Scholar
22 Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol.165(4),1992–2000 (2000).
Medline CASGoogle Scholar
23 Vitale S, Cambien B, Karimdjee BF et al. Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut56(3),365–372 (2007).
Medline CASGoogle Scholar
24 Wang YQ, Wada A, Ugai S, Tagawa M. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. Oncol. Rep.10(4),909–913 (2003).
Medline CASGoogle Scholar
25 Okada N, Gao JQ, Sasaki A et al. Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapy. Biochem. Biophys. Res. Commun.317(1),68–76 (2004).
Medline CASGoogle Scholar
26 Braun SE, Chen K, Foster RG et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J. Immunol.164(8),4025–4031 (2000).
Medline CASGoogle Scholar
27 Fioretti F, Fradelizi D, Stoppacciaro A et al. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J. Immunol.161(1),342–346 (1998).
Medline CASGoogle Scholar
28 Hu JY, Li GC, Wang WM et al. Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. World J. Gastroenterol.8(6),1067–1072 (2002).
Medline CASGoogle Scholar
29 Cairns CM, Gordon JR, Li F, Baca-Estrada ME, Moyana T, Xiang J. Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4⁺ and CD8⁺ T cells and neutrophils expressing XCR1 receptor. J. Immunol.167(1),57–65 (2001).
Medline CASGoogle Scholar
30 Rousseau RF, Haight AE, Hirschmann-Jax C et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood101(5),1718–1726 (2003).
Medline CASGoogle Scholar
31 Gao JQ, Tsuda Y, Katayama K et al. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. Cancer Res.63(15),4420–4425 (2003).
Medline CASGoogle Scholar
32 Okada N. Cell delivery system: a novel strategy to improve the efficacy of cancer immunotherapy by manipulation of immune cell trafficking and biodistribution. Biol. Pharm. Bull.28(9),1543–1550 (2005).▪ Emphasis on vaccine created by CCR7 gene transduction to manipulate immune cell trafficking and biodistribution in cancer immunotherapy.
Medline CASGoogle Scholar
33 Janikashvili N, Larmonier N, Katsanis E. Personalized dendritic cell-based tumor immunotherapy. Immunotherapy2(1),57–68 (2010).
CASGoogle Scholar
34 Murugaiyan G, Saroj Basak S, Saha B. Dendritic cell-based immunotherapy: a promising approach for treatment of cancer. Gene Ther. Mol. Biol.9,343–358 (2005).
Google Scholar
35 Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res.16(3),241–259 (2006).
Medline CASGoogle Scholar
36 Kirk CJ, Hartigan-O’connor D, Nickoloff BJ et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res.61(5),2062–2070 (2001).
Medline CASGoogle Scholar
37 Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J. Immunol.172(2),776–786 (2004).
Medline CASGoogle Scholar
38 Matsuyoshi H, Hirata S, Yoshitake Y et al. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci.96(12),889–896 (2005).
Medline CASGoogle Scholar
39 Zhang W, He L, Cao X. Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide. Zhonghua Yi Xue Za Zhi79(3),170–173 (1999).
Medline CASGoogle Scholar
40 Cao X, Zhang W, He L et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol.161(11),6238–6244 (1998).
Medline CASGoogle Scholar
41 Zhang W, He L, Yuan Z et al. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther.10(7),1151–1161 (1999).
Medline CASGoogle Scholar
42 Xia DJ, Zhang WP, Zheng S et al. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Gene Ther.9(9),592–601 (2002).
Medline CASGoogle Scholar
43 Gao JQ, Okada N, Mayumi T, Nakagawa S. Immune cell recruitment and cell-based system for cancer therapy. Pharm. Res.25(4),752–768 (2008).
Medline CASGoogle Scholar
44 Dubinett SM, Lee JM, Sharma S, Mule JJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J.16(4),325–335 (2010).
Medline CASGoogle Scholar
45 Terando A, Roessler B, Mule JJ. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther.11(3),165–173 (2004).
Medline CASGoogle Scholar
46 Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery systems. Pharmaceut. Med.25(5),293–306 (2011).
MedlineGoogle Scholar
47 Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J.17(5),359–371 (2011).
Medline CASGoogle Scholar
48 Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer10,3 (2011).
Medline CASGoogle Scholar
49 Guiducci C, Di Carlo E, Parenza M et al. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J. Immunol.172(7),4026–4036 (2004).
Medline CASGoogle Scholar
50 Hou JM, Zhao X, Tian L et al. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice. Acta Pharmacol. Sin.30(3),355–363 (2009).
Medline CASGoogle Scholar
51 Kanagawa N, Niwa M, Hatanaka Y et al. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int. J. Cancer121(9),2013–2022 (2007).
Medline CASGoogle Scholar
52 Okada N, Sasaki A, Niwa M et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther.13(4),393–405 (2006).
Medline CASGoogle Scholar
53 Wetzel K, Struyf S, Van Damme J et al. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int. J. Cancer120(6),1364–1371 (2007).
Medline CASGoogle Scholar
54 Giese NA, Raykov Z, Demartino L et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther.9(5),432–442 (2002).
Medline CASGoogle Scholar
55 Flanagan K, Glover RT, Horig H, Yang W, Kaufman HL. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine22(21–22),2894–2903 (2004).
Medline CASGoogle Scholar
56 Kutubuddin M, Federoff HJ, Challita-Eid PM et al. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood93(2),643–654 (1999).
Medline CASGoogle Scholar
57 Shimizu Y, Inaba K, Kaneyasu K et al. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques. Virology361(1),68–79 (2007).
Medline CASGoogle Scholar
58 Villatoro-Hernandez J, Loera-Arias MJ, Gamez-Escobedo A et al. Secretion of biologically active interferon-gamma inducible protein-10 (IP-10) by Lactococcus lactis. Microb. Cell Fact.7,22 (2008).▪ Describes novel live nonpathogenic and food-grade lactic-acid bacterium for chemokine delivery.
MedlineGoogle Scholar
59 Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nature Rev. Immunol.6(2),148–158 (2006).
Medline CASGoogle Scholar
60 Zavala-Flores LM, Villatoro-Hernandez J, Gamez-Escobedo A et al. Production of biologically active human lymphotactin (XCL1) by Lactococcus lactis. Biotechnol. Lett.31(2),215–220 (2009).
Medline CASGoogle Scholar
61 Villatoro-Hernandez J, Arce-Mendoza AY, Rosas-Taraco AG et al. Murine interferon-gamma inducible protein-10 (IP-10) secreted by Lactococcus lactis chemo-attracts human CD3⁺ lymphocytes. Biotechnol. Lett.31(11),1795–1800 (2009).
Medline CASGoogle Scholar
62 Cortes-Perez NG, Da Costa Medina LF, Lefevre F, Langella P, Bermudez-Humaran LG. Production of biologically active CXC chemokines by Lactococcus lactis: evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine26(46),5778–5783 (2008).
Medline CASGoogle Scholar
63 Xiang R, Mizutani N, Luo Y et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res.65(2),553–561 (2005).
Medline CASGoogle Scholar
64 Ryan AA, Spratt JM, Britton WJ, Triccas JA. Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection. Infect. Immun.75(1),523–526 (2007).
Medline CASGoogle Scholar
65 Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr. Gene Ther.2(2),183–194 (2002).
Medline CASGoogle Scholar
66 Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum. Gene Ther.12(8),861–870 (2001).
Medline CASGoogle Scholar
67 Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res.26(3),502–511 (2009).
Medline CASGoogle Scholar
68 Lenter MC, Garidel P, Pelisek J, Wagner E, Ogris M. Stabilized nonviral formulations for the delivery of MCP-1 gene into cells of the vasculoendothelial system. Pharm. Res.21(4),683–691 (2004).
Medline CASGoogle Scholar
69 Oh YK, Park JS, Yoon H, Kim CK. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine21(17–18),1980–1988 (2003).▪ Describes chemokine-based combinational therapy using a delivery system for induction of mucosal immunity.
Medline CASGoogle Scholar
70 Kar UK, Srivastava MK, Andersson A et al. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PloS ONE6(5),e18758 (2011).
Medline CASGoogle Scholar
71 Narvaiza I, Mazzolini G, Barajas M et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol.164(6),3112–3122 (2000).
Medline CASGoogle Scholar
72 Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther.8(4),282–290 (2001).
Medline CASGoogle Scholar
73 Gao JQ, Kanagawa N, Motomura Y et al. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther.14(6),491–502 (2007).
Medline CASGoogle Scholar
74 Guo JQ, Chen L, Ai HW et al. A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function. Biochem. Biophys. Res. Commun.320(2),506–513 (2004).
Medline CASGoogle Scholar
75 Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol. Ther.7(11),1705–1721 (2007).
Medline CASGoogle Scholar
76 Kanegane C, Sgadari C, Kanegane H et al. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukoc. Biol.64(3),384–392 (1998).
Medline CASGoogle Scholar
77 Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood87(9),3877–3882 (1996).
Medline CASGoogle Scholar
78 Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol27(1),58–63 (1999).
Medline CASGoogle Scholar
79 Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS et al. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther.19(1),69–76 (2012).
Medline CASGoogle Scholar
80 Nomura T, Hasegawa H, Kohno M, Sasaki M, Fujita S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int. J. Cancer91(5),597–606 (2001).
Medline CASGoogle Scholar
81 Inoue H, Iga M, Xin M et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol. Immunother.57(9),1399–1411 (2008).
Medline CASGoogle Scholar
82 Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4⁽⁺⁾ T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol.74(23),11173–11180 (2000).
Medline CASGoogle Scholar
83 Huang H, Xiang J. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int. J. Cancer109(6),817–825 (2004).
Medline CASGoogle Scholar
84 Tominaga M, Iwashita Y, Ohta M et al. Antitumor effects of the MIG and IP-10 genes transferred with poly [D,L-2,4-diaminobutyric acid] on murine neuroblastoma. Cancer Gene Ther.14(8),696–705 (2007).▪▪ Explains the combination of chemokine and delivery system to enhance antitumor effects.
Medline CASGoogle Scholar
85 Zhang R, Tian L, Chen LJ et al. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther.13(17),1263–1271 (2006).
Medline CASGoogle Scholar
86 Li G, Tian L, Hou JM et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin. Cancer Res.11(11),4217–4224 (2005).
Medline CASGoogle Scholar
87 Mei K, Wang L, Tian L, Yu J, Zhang Z, Wei Y. Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model. J. Exp. Clin. Cancer Res.27,63 (2008).
MedlineGoogle Scholar
88 Tsuchiyama T, Nakamoto Y, Sakai Y et al. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J. Immunol.178(1),574–583 (2007).
Medline CASGoogle Scholar
89 Chen P, Yang LL, Yang HS et al. Synergistic antitumor effect of CXCL10 with hyperthermia. J. Cancer Res. Clin. Oncol.134(6),679–687 (2008).
Medline CASGoogle Scholar
90 Yoon HA, Eo SK. Differential polarization of immune responses by genetic cotransfer of chemokines changes the protective immunity of DNA vaccine against pseudorabies virus. Immunology120(2),182–191 (2007).
Medline CASGoogle Scholar
91 Westermann J, Nguyen-Hoai T, Baldenhofer G et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a Th1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther.14(6),523–532 (2007).
Medline CASGoogle Scholar
92 Lietz R, Bayer W, Ontikatze T et al. Co-delivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J. Virol.86(3),1706–1716 (2011).
MedlineGoogle Scholar
93 Fredriksen AB, Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood110(6),1797–1805 (2007).
Medline CASGoogle Scholar
94 Ruffini PA, Grodeland G, Fredriksen AB, Bogen B. Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine29(2),191–199 (2010).
Medline CASGoogle Scholar
95 Aravindaram K, Yu HH, Lan CW et al. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma. Gene Ther.16(11),1329–1339 (2009).
Medline CASGoogle Scholar
96 Kim SJ, Lee C, Lee SY et al. Enhanced immunogenicity of human papillomavirus 16 L1 genetic vaccines fused to an ER-targeting secretory signal peptide and RANTES. Gene Ther.10(15),1268–1273 (2003).
Medline CASGoogle Scholar
97 Kim SJ, Suh D, Park SE et al. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology314(1),84–91 (2003).
Medline CASGoogle Scholar
98 Williman J, Young S, Buchan G et al. DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza. Vaccine26(40),5153–5158 (2008).
Medline CASGoogle Scholar
99 Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood100(4),1153–1159 (2002).
Medline CASGoogle Scholar
100 Qin H, Nehete PN, He H et al. Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques. J. Biomed. Biotechnol.2010,860160 (2010).
MedlineGoogle Scholar
101 Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol.17(3),253–258 (1999).
Medline CASGoogle Scholar
102 Kang TH, Kim KW, Bae HC, Seong SY, Kim TW. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int. J. Cancer128(3),702–714 (2011).▪ Original article describing the use of IP-10 for enhancing herpes simplex virus therapeutic vaccine.
Medline CASGoogle Scholar
103 Challita-Eid PM, Abboud CN, Morrison SL et al. A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J. Immunol.161(7),3729–3736 (1998).
Medline CASGoogle Scholar
104 Li J, Hu P, Khawli LA, Epstein AL. LEC/chTNT-3 fusion protein for the immunotherapy of experimental solid tumors. J. Immunother.26(4),320–331 (2003).
MedlineGoogle Scholar
105 Liu R, Zhou C, Wang D et al. Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes. Cancer Biol. Ther.5(4),427–434 (2006).
MedlineGoogle Scholar
106 Qin H, Zhou C, Wang D et al. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology117(3),419–430 (2006).
Medline CASGoogle Scholar
107 Lavergne E, Combadiere C, Iga M et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J. Immunol.173(6),3755–3762 (2004).
Medline CASGoogle Scholar
108 Dorgham K, Abadie V, Iga M, Hartley O, Gorochov G, Combadiere B. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine26(26),3252–3260 (2008).
Medline CASGoogle Scholar
109 Iga M, Boissonnas A, Mahe B, Bonduelle O, Combadiere C, Combadiere B. Single CX3CL1-Ig DNA administration enhances T cell priming in vivo. Vaccine25(23),4554–4563 (2007).
Medline CASGoogle Scholar
110 Khawli LA, Hu P, Epstein AL. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb. Exp. Pharmacol. (181),291–328 (2008).
MedlineGoogle Scholar
111 Jia Y, Li H, Chen W et al. Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther.13(18),1351–1359 (2006).
Medline CASGoogle Scholar
112 Chen W, Li H, Jia Y et al.In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J. Autoimmun.28(1),30–40 (2007).
MedlineGoogle Scholar
113 Kuroda T, Kitadai Y, Tanaka S et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res.11(21),7629–7636 (2005).
Medline CASGoogle Scholar
114 Nagai M, Masuzawa T. Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Int. Immunopharmacol.1(4),657–664 (2001).
Medline CASGoogle Scholar
115 Nishioka Y, Yano S, Fujiki F et al. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int. J. Cancer71(2),170–177 (1997).
Medline CASGoogle Scholar
116 Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther.12(4),359–368 (2005).
Medline CASGoogle Scholar
117 Nakashima E, Mukaida N, Kubota Y et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res.12(11),1598–1604 (1995).
Medline CASGoogle Scholar
118 Lu Y, Xin KQ, Hamajima K et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin. Exp. Immunol.115(2),335–341 (1999).
Medline CASGoogle Scholar
119 Youssef S, Wildbaum G, Maor G et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol.161(8),3870–3879 (1998).
Medline CASGoogle Scholar
120 Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 naked DNA vaccines. J. Autoimmun.13(1),21–29 (1999).
Medline CASGoogle Scholar
121 Bhattacharyya S, Ghosh S, Dasgupta B, Mazumder D, Roy S, Majumdar S. Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J. Infect. Dis.185(12),1704–1708 (2002).
Medline CASGoogle Scholar
122 Brandonisio O, Panaro MA, Fumarola I et al. Macrophage chemotactic protein-1 and macrophage inflammatory protein-1 alpha induce nitric oxide release and enhance parasite killing in Leishmania infantum-infected human macrophages. Clin. Exp. Med.2(3),125–129 (2002).
Medline CASGoogle Scholar
123 Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol. Ther.10(5),725–733 (2010).▪▪ Comprehensive review of CCL5 that highlights its dual role in cancer development.
Medline CASGoogle Scholar
124 Song S, Liu C, Wang J et al. Vaccination with combination of Fit3L and RANTES in a DNA prime–protein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine27(7),1111–1118 (2009).
Medline CASGoogle Scholar
125 Lapteva N, Aldrich M, Weksberg D et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother.32(2),145–156 (2009).
Medline CASGoogle Scholar
126 Manes S, Mira E, Colomer R et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J. Exp. Med198(9),1381–1389 (2003).
Medline CASGoogle Scholar
127 Xin KQ, Lu Y, Hamajima K et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin. Immunol.92(1),90–96 (1999).
Medline CASGoogle Scholar
128 Frauenschuh A, Devico AL, Lim SP, Gallo RC, Garzino-Demo A. Differential polarization of immune responses by co-administration of antigens with chemokines. Vaccine23(4),546–554 (2004).
Medline CASGoogle Scholar
129 Ma K, Xu W, Shao X et al. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells. Antiviral Res.76(2),140–149 (2007).
Medline CASGoogle Scholar
130 Villalta F, Zhang Y, Bibb KE, Kappes JC, Lima MF. The cysteine-cysteine family of chemokines RANTES, MIP-1alpha, and MIP-1beta induce trypanocidal activity in human macrophages via nitric oxide. Infect. Immun.66(10),4690–4695 (1998).
Medline CASGoogle Scholar
131 Wetzel K, Menten P, Opdenakker G et al. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J. Gene Med.3(4),326–337 (2001).
Medline CASGoogle Scholar
132 Giovarelli M, Cappello P, Forni G et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J. Immunol.164(6),3200–3206 (2000).
Medline CASGoogle Scholar
133 Musiani P, Modesti A, Giovarelli M et al. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today18(1),32–36 (1997).
Medline CASGoogle Scholar
134 Hornick JL, Sharifi J, Khawli LA et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother. Radiopharm.13(4),255–268 (1998).
Medline CASGoogle Scholar
135 Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25⁽⁺⁾ T-cell depletion. Cancer Res.63(23),8384–8392 (2003).
Medline CASGoogle Scholar
136 Hillinger S, Yang SC, Zhu L et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J. Immunol.171(12),6457–6465 (2003).
Medline CASGoogle Scholar
137 Han YW, Aleyas AG, George JA et al. Genetic co-transfer of CCR7 ligands enhances immunity and prolongs survival against virulent challenge of pseudorabies virus. Immunol. Cell Biol.87(1),91–99 (2009).
Medline CASGoogle Scholar
138 Mandai M, Hamanishi J, Abiko K et al. Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells. Horm. Cancer1(6),291–296 (2010).
Medline CASGoogle Scholar
139 Baba M, Imai T, Nishimura M et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J. Biol. Chem.272(23),14893–14898 (1997).
Medline CASGoogle Scholar
140 Guo JH, Fan MW, Sun JH, Jia R. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int. Immunopharmacol.9(7–8),925–930 (2009).
Medline CASGoogle Scholar
141 He S, Wang L, Wu Y, Li D, Zhang Y. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J. Exp. Clin. Cancer Res.29,37 (2010).
MedlineGoogle Scholar
142 Liang CM, Zhong CP, Sun RX et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J. Virol.81(17),9502–9511 (2007).
Medline CASGoogle Scholar
143 Wu S, Lu X, Zhang ZL et al. CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2. Carcinogenesis32(3),296–304 (2011).
Medline CASGoogle Scholar
144 Flanagan K, Moroziewicz D, Kwak H, Horig H, Kaufman HL. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4⁺ T cells. Cell. Immunol.231(1–2),75–84 (2004).
Medline CASGoogle Scholar
145 Sharma S, Yang SC, Hillinger S et al. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol. Cancer2,22 (2003).
MedlineGoogle Scholar
146 Yamano T, Kaneda Y, Hiramatsu SH et al. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther.14(5),451–459 (2007).
Medline CASGoogle Scholar
147 Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol. Ther.13(1),194–202 (2006).
Medline CASGoogle Scholar
148 Nomura T, Hasegawa H. Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res.20(6A),4073–4080 (2000).
Medline CASGoogle Scholar
149 Li N, Qin H, Li X et al. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. J. Clin. Immunol.27(1),117–130 (2007).
MedlineGoogle Scholar
150 Oh SM, Oh K, Lee DS. Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo. J. Korean Med. Sci.26(10),1270–1276 (2011).
Medline CASGoogle Scholar
151 Warren P, Song W, Holle E et al. Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice. Anticancer Res.22(2A),599–604 (2002).
Medline CASGoogle Scholar
152 Tolba KA, Bowers WJ, Muller J et al. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Res.62(22),6545–6551 (2002).
Medline CASGoogle Scholar
153 Hisada M, Yoshimoto T, Kamiya S et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther.11(4),280–288 (2004).
Medline CASGoogle Scholar
154 Kirk CJ, Hartigan-O’connor D, Mule JJ. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res.61(24),8794–8802 (2001).
Medline CASGoogle Scholar
155 Yang SC, Hillinger S, Riedl K et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin. Cancer Res.10(8),2891–2901 (2004).
Medline CASGoogle Scholar
156 Yang SC, Batra RK, Hillinger S et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res.66(6),3205–3213 (2006).
Medline CASGoogle Scholar
157 Baratelli F, Takedatsu H, Hazra S et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a Phase I trial in non-small cell lung cancer. J. Transl Med.6,38 (2008).
MedlineGoogle Scholar
158 Okada N, Mori N, Koretomo R et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther.12(2),129–139 (2005).
Medline CASGoogle Scholar
159 Sharma S, Stolina M, Luo J et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol.164(9),4558–4563 (2000).
Medline CASGoogle Scholar
160 Eo SK, Kumaraguru U, Rouse BT. Plasmid DNA encoding CCR7 ligands compensate for dysfunctional CD8⁺ T cell responses by effects on dendritic cells. J. Immunol.167(7),3592–3599 (2001).
Medline CASGoogle Scholar
161 Lee Y, Eo SK, Rouse RJ, Rouse BT. Influence of CCR7 ligand DNA preexposure on the magnitude and duration of immunity. Virology312(1),169–180 (2003).
Medline CASGoogle Scholar
162 Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine19(32),4685–4693 (2001).
Medline CASGoogle Scholar
163 Vulcano M, Albanesi C, Stoppacciaro A et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol.31(3),812–822 (2001).
Medline CASGoogle Scholar
164 Lee JM, Merritt RE, Mahtabifard A et al. Intratumoral expression of macrophage-derived chemokine induces CD4⁺ T cell-independent antitumor immunity in mice. J. Immunother.26(2),117–129 (2003).
Medline CASGoogle Scholar
165 Guo J, Wang B, Zhang M et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther.9(12),793–803 (2002).
Medline CASGoogle Scholar
166 Morales J, Homey B, Vicari AP et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl Acad. Sci. USA96(25),14470–14475 (1999).
Medline CASGoogle Scholar
167 Kutzler MA, Kraynyak KA, Nagle SJ et al. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther.17(1),72–82 (2010).
Medline CASGoogle Scholar
168 Kraynyak KA, Kutzler MA, Cisper NJ et al. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine28(8),1942–1951 (2010).
Medline CASGoogle Scholar
169 Whiting D, Hsieh G, Yun JJ et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J. Immunol.172(12),7417–7424 (2004).
Medline CASGoogle Scholar
170 Sgadari C, Farber JM, Angiolillo AL et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood89(8),2635–2643 (1997).
Medline CASGoogle Scholar
171 Addison CL, Arenberg DA, Morris SB et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum. Gene Ther.11(2),247–261 (2000).
Medline CASGoogle Scholar
172 Xiang R, Lode HN, Dolman CS et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res.57(21),4948–4955 (1997).
Medline CASGoogle Scholar
173 Ruehlmann JM, Xiang R, Niethammer AG et al.MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res.61(23),8498–8503 (2001).
Medline CASGoogle Scholar
174 Yang X, Chu Y, Wang Y, Zhang R, Xiong S. Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J. Leukoc. Biol.80(6),1434–1444 (2006).
Medline CASGoogle Scholar
175 Feldman ED, Weinreich DM, Carroll NM et al. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann. Surg. Oncol.13(1),125–133 (2006).
MedlineGoogle Scholar
176 Bodnar RJ, Yates CC, Wells A. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ. Res.98(5),617–625 (2006).
Medline CASGoogle Scholar
177 Keyser J, Schultz J, Ladell K et al. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. Exp. Dermatol.13(6),380–390 (2004).
Medline CASGoogle Scholar
178 Arenberg DA, Kunkel SL, Polverini PJ et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med184(3),981–992 (1996).
Medline CASGoogle Scholar
179 Sgadari C, Angiolillo AL, Cherney BW et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl Acad. Sci. USA93(24),13791–13796 (1996).
Medline CASGoogle Scholar
180 Iwashita Y, Ogawa T, Goto S, Nakanishi M, Goto T, Kitano S. Effective transfer of interleukin-12 gene to solid tumors using a novel gene delivery system, poly [D,L-2,4-diaminobutyric acid]. Cancer Gene Ther.11(2),103–108 (2004).
Medline CASGoogle Scholar
181 Alexis F, Lo S, Wang S. Covalent attachment of low molecular weight poly(ethyleneimine) improves Tat peptide mediated gene delivery. Adv. Mater.18(16),2174–2178 (2006).
CASGoogle Scholar
182 Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug. Deliv.16(4),196–204 (2009).
Medline CASGoogle Scholar
183 Lu XL, Jiang XB, Liu RE, Zhang SM. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10. Vaccine26(42),5352–5357 (2008).
Medline CASGoogle Scholar
184 Jiang XB, Lu XL, Hu P, Liu RE. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine27(44),6210–6216 (2009).
Medline CASGoogle Scholar
185 Guo JQ, Li QM, Zhou JY et al. Efficient recovery of the functional IP10-scFv fusion protein from inclusion bodies with an on-column refolding system. Protein Expr. Purif.45(1),168–174 (2006).
Medline CASGoogle Scholar
186 Zeng X, Moore TA, Newstead MW, Deng JC, Lukacs NW, Standiford TJ. IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. J. Interferon Cytokine Res.25(2),103–112 (2005).
Medline CASGoogle Scholar
187 Rodriguez MM, Ryu SM, Qian C et al. Immunotherapy of murine hepatocellular carcinoma by alpha-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression. Hum. Gene Ther.19(7),753–759 (2008).
Medline CASGoogle Scholar
188 Liu Y, Huang H, Saxena A, Xiang J. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther.9(6),533–542 (2002).
Medline CASGoogle Scholar
189 Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell. Immunol.217(1–2),12–22 (2002).
Medline CASGoogle Scholar
190 Enderlin M, Kleinmann EV, Struyf S et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther.16(2),149–160 (2009).
Medline CASGoogle Scholar
191 Krathwohl MD, Anderson JL. Chemokine CXCL10 (IP-10) is sufficient to trigger an immune response to injected antigens in a mouse model. Vaccine24(15),2987–2993 (2006).
Medline CASGoogle Scholar
192 Zeng X, Moore TA, Newstead MW et al. Interferon-inducible protein 10, but not monokine induced by gamma interferon, promotes protective type 1 immunity in murine Klebsiella pneumoniae pneumonia. Infect. Immun.73(12),8226–8236 (2005).
Medline CASGoogle Scholar
193 Wiley R, Palmer K, Gajewska B et al. Expression of the Th1 chemokine IFN-gamma-inducible protein 10 in the airway alters mucosal allergic sensitization in mice. J. Immunol.166(4),2750–2759 (2001).
Medline CASGoogle Scholar
194 Vasquez RE, Soong L. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect. Immun.74(12),6769–6777 (2006).
Medline CASGoogle Scholar
195 Muller K, Van Zandbergen G, Hansen B et al. Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med. Microbiol. Immunol.190(1–2),73–76 (2001).
Medline CASGoogle Scholar
196 Vasquez RE, Xin L, Soong L. Effects of CXCL10 on dendritic cell and CD4⁺ T-cell functions during Leishmania amazonensis infection. Infect. Immun.76(1),161–169 (2008).
Medline CASGoogle Scholar
197 Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun.73(10),6372–6382 (2005).
Medline CASGoogle Scholar
198 Mizbani A, Taheri T, Zahedifard F et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine28(1),53–62 (2009).▪ Ellucidates Leishmania tarentolae as a live vaccine vector.
MedlineGoogle Scholar
199 Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol88(Pt 1),217–225 (2007).▪ Elucidates L. tarentolae as a live vaccine vector for expressing non-Leishmania gene.
Medline CASGoogle Scholar
200 Huang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem. Biophys. Res. Commun.281(2),378–382 (2001).
Medline CASGoogle Scholar
201 Huang H, Li F, Gordon JR, Xiang J. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4⁺ and CD8⁺ T cells and intratumoral lymphotactin transgene expression. Cancer Res.62(7),2043–2051 (2002).
Medline CASGoogle Scholar
202 Huang H, Bi XG, Yuan JY, Xu SL, Guo XL, Xiang J. Combined CD4⁺ Th1 effect and lymphotactin transgene expression enhance CD8⁺ Tc1 tumor localization and therapy. Gene Ther.12(12),999–1010 (2005).
Medline CASGoogle Scholar
203 Dilloo D, Bacon K, Holden W et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med.2(10),1090–1095 (1996).
Medline CASGoogle Scholar
204 Emtage PC, Wan Y, Hitt M et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to fo facilitate tumor regression in murine breast cancer models. Hum. Gene Ther.10(5),697–709 (1999).
Medline CASGoogle Scholar
205 Russell HV, Strother D, Mei Z et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J. Immunother.30(2),227–233 (2007).▪ Describes one of the clinical trials that used chemokine-based immunotherapy.
Medline CASGoogle Scholar
206 Hundhausen C, Misztela D, Berkhout TA et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood102(4),1186–1195 (2003).
Medline CASGoogle Scholar
207 Zeng Y HN, Fest S, Weixler S et al. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res.67(5),2331–2338 (2007).
Medline CASGoogle Scholar
208 Lavergne E, Combadiere B, Bonduelle O et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res.63(21),7468–7474 (2003).
MedlineGoogle Scholar
209 Guo J, Chen T, Wang B et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1. Immunol. Lett.89(1),1–7 (2003).
Medline CASGoogle Scholar
210 Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl Cancer Inst.89(21),1586–1594 (1997).
Medline CASGoogle Scholar
211 Zeng Y, Jiang J, Huebener N et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett.228(1–2),187–193 (2005).
Medline CASGoogle Scholar
212 Gao JQ, Kanagawa N, Xu DH et al. Combination of two fiber-mutant adenovirus vectors, one encoding the chemokine FKN and another encoding cytokine interleukin 12, elicits notably enhanced anti-tumor responses. Cancer Immunol. Immunother.57(11),1657–1664 (2008).
Medline CASGoogle Scholar
213 Nukiwa M, Andarini S, Zaini J et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur. J. Immunol.36(4),1019–1027 (2006).
Medline CASGoogle Scholar

Vol. 4, No. 8

Metrics

Downloaded 269 times

History

Published online 4 September 2012

Published in print August 2012

Information

Keywords

Acknowledgements

The authors wish to acknowledge the English editing performed by A Mizbani.

Financial & competing interests disclosure

E Mohit thanks the Pasteur Institute of Iran for the grants supporting her PhD studentship. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Chemokine-based immunotherapy: delivery systems and combination therapies

Abstract

References